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Abstract
Background: We have previously demonstrated that estrogen could significantly enhance expression
of apolipoprotein M (apoM), whereas the molecular basis of its mechanism is not fully elucidated yet.
To further investigate the mechanism behind the estrogen induced up-regulation of apoM expression.
Results: Our results demonstrated either free 17β-estradiol (E2) or membrane-impermeable bovine serum
albumin-conjugated E2 (E2-BSA) could modulate human apoM gene expression via the estrogen receptor
alpha (ER-α) pathway in the HepG2 cells. Moreover, experiments with the luciferase activity analysis of
truncated apoM promoters could demonstrate that a regulatory region (from-1580 to −1575 bp (−GGTCA-))
upstream of the transcriptional start site of apoM gene was essential for the basal transcriptional activity
that regulated by the ER-α. With the applications of an electrophoresis mobility shift assay and a chromatin
immunoprecipitation assay, we could successfully identify a specific ER-α binding element in the apoM
promoter region.
Conculsion: In summary, the present study indicates that 17β-estradiol induced up-regulation of apoM in
HepG2 cells is through an ER-α-dependent pathway involving ER-α binding element in the promoter of the
apoM gene.
Keywords: Estrogen receptor alpha, Apolipoprotein M, Estrogen responsive element, Electrophoretic
mobility shift assay (EMSA), Chromatin Immunoprecipitation (ChIP) assay
Background
Apolipoprotein M (apoM) is mainly located in high
density lipoprotein (HDL) in human plasma, with only a
small proportion presented in low density lipoprotein
(LDL) and very low density lipoprotein (VLDL) particles
[1]. In humans and mice, apoM is mainly expressed in
hepatocytes and in kidney proximal tubule epithelial
cells [2, 3]. The apoM-containing lipoproteins were pre-
dominantly of HDL size, and about 5% of the total HDL
population contained apoM in human plasma [4].
Wolfrum and his colleagues, by using apoM-deficient
mice, demonstrated that apoM is important for preβ-
HDL formation and cholesterol efflux from macro-
phages; thus, apoM-deficient HDL was markedly less
efficient in facilitating cholesterol efflux from macro-
phages in vitro than normal HDL [5]. Moreover, over-
expression of apoM in LDL-receptor knock-out mice
protected against atherosclerosis when fed a high choles-
terol diet [5]. Recently, apoM was shown to be a carrier
for sphingosine 1-phosphate (S1P), a bioactive lipid me-
diator. HDL-associated S1P is bound specifically to both
human and murine apoM. Isolated human apoM+ HDL
contained S1P, whereas apoM−HDL did not. Moreover,
HDL in apoM−/−mice contains no S1P, whereas HDL in
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transgenic mice overexpressing human apoM has an in-
creased S1P content [6]. In another study it showed that
hepatic overexpression of apoM could stimulate forma-
tion of larger apoM/sphingosine 1-phosphate-enriched
high density lipoprotein in plasma [7]. It is well known
that S1P is a critical regulator of many physiological and
pathophysiological processes, including cancer, athero-
sclerosis, diabetes and osteoporosis [8].
We have previously demonstrated that estrogen could
significantly enhance the expression of apoM in dose-
dependent and time-dependent manner, whereas the
molecular basis of its mechanism is unknown yet [9]. In
general the action of estrogen can be mediated by the
classic nuclear estrogen receptors (ER), ER-αand ER-β or
through membrane receptors. Mechanisms by which
ER-α and ER-β bind ligand, dimerize, associate with en-
hancers or corepressors, and regulate gene transcription
through binding to target genes, are well known and are
typically referred to as genomic actions. In addition,
membrane associated ERs mediate nongenomic actions
of estrogens. These responses occur rapidly, within
seconds to few minute. ER-α is one of estrogen re-
ceptor family. It is mainly expressed in reproductive
tissues, kidney, bone, white adipose tissues and liver,
and localized in nucleus, plasma member and mito-
chondria [10, 11]. Haas et al. examined the effects of
isoflavones (quercetin, isoquercetin, and myricetin) on
apoA-I gene expression in HepG2 and Caco-2 cells.
They reported that quercetin could upregulate apoA-I
gene expression at least in part by ER-α, which might
be applicable for the treatment of hypoalphalipopro-
teinemia [12]. As a major component of HDL, apoA-I
help to clear fats, including cholesterol, from white
blood cells within artery walls, making the white
blood cells less likely to become fat overloaded, transform
into foam cells, die and contribute to progressive ather-
oma. Moreover, estrogen stimulates expression of chicken
hepatic vitellogenin II and very low density apolipoprotein
II through ER-α [13].
Methods
Materials
The HepG2 and MCF-7cell lines were obtained from the
American Type Culture Collection (Manassas, VA,
USA). Six-well cell culture clusters and 75 cm2 vented
cell culture flasks were purchased from Nunc (Roskilde,
Denmark). 17β-estradiol (E2) and E2 Conjugated with
Bovine Serum Albumin (E2-BSA, membrane imperme-
able E2) from sigma chemical Co.Ltd. (Shanghai, China).
Fetal bovine serum (FBS), DMEM, phenol red-free
DMEM and charcoal treated FBS were obtained from
Wissent (Nanjing, China).1,3-Bis(4-hydroxyphenyl)-4-
methyl-5-[4–2-piperidinyletho- xy)phenol]-1H–pyrazole
(MPP) dihydrochloride was purchased from Tocris
bioscience Co. Ltd. (Shanghai, China). Rabbit anti-
human apoM monoclonal antibodies were from
Abnova Corporation (Taiwan, china). Total RNA puri-
fication kits were purchased from the Shenergy Bioco-
lor BioScience and Technology Company (Shanghai,
China). First strand cDNA synthesis kitswere obtained
from Fermantas (Vilnius, Lithuania). The LightCycler
real-time RT-PCR System was from Roche Applied
Science (Mannheim, Germany).
Cell cultures
HepG2 and MCF-7 cells were cultured in DMEM sup-
plemented with 10% FBS in the presence of 100 U/ml
penicillin, 100 μg/ml streptomycin and 1% Glutamax at
37 °C under 5% CO2 atmosphere. HepG2 cells were
plated in 6-well cell culture clusters at a density of
5 × 104 cells/dish with phenol red–free DMEM contain-
ing 10% charcoal-treated FBS. Cell monolayers of
approximately 50–70% confluence were grown for 24 h
in the above media, then washed and incubated in
serum-free medium with different concentrations of of
E2-BSA(1 ~ 100 nM) for 24 h, before extraction of total
RNA. In the antagonism study, we used E2 (10 μM) or
E2-BSA (100 nM) and MPP (1 μM) in the culture
medium. E2 and MPP were dissolved in ethanol, E2-
BSA was dissolved in DMEM.
Total RNA extraction and real time RT-PCR
Total RNA extraction and real time RT-PCR were re-
ferred as our previous methods [9]. In brief, quantifica-
tions of apoM mRNA levels are relative to mRNA level
of GAPDH, and were performed on a LightCycler in a
final volume of 25 μl. Optimum reaction conditions
were obtained with 2.5 μl of 10 × PCR buffer, 1.5 μl of
25 mM MgCl2, 0.5 μl of 10 mM 4 × dNTPs, 0.25 μl of
5 U/μl common Taq DNA polymerase, 0.1 μl of 100 μM
specific sense primer(s), 0.1 μl of 100 μM specific anti-
sense primer(s), 0.1 μl of 100 μM specific probe(s) and
2 μl template cDNA. Finally 17.95 μl ddH2O was added
to the reaction mixture. The thermal cycling conditions
for GAPDH and apoM included the following steps: 25 °C
for 10 min, 48 °C for 30 min and 95 °C for 5 min to do re-
verse transcription, and then the reaction mixture was
preheated for for 3 min at 95 °C. After that, a 40-cycle
two-step PCR was performed consisting of 5 s at 95 °C
and 27 s at 58 °C. Samples were amplified simultaneously
in triplicates in one-assay run.
Western blot analysis
ApoM concentrations in cells were measured by western
blot analysis [9]. In brief, for cell extract preparation,
cells were resuspended in RIPA lysis buffer. Aliquots of
cell extracts were resolved on a 10% SDS-polyacrylamide
gel electrophoresis, transferred electrophoretically to
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nitrocellulose membranes, and the primary antibodies
used were apoM and GAPDH. Horseradish peroxidase-
conjugated second antibody was used in conjunction
with ECL chemiluminescence detection system
(Amersham) and quantified by a scanner using the
Quqntity One software (Version 4.2.1, Bio-Rad
Laboratories).
Construction of the human apoM activated luciferase
(hapoM-luc) reporter plasmids
Genome DNA was isolated from the MCF-7 cells using
a DNA extraction kit (QIAGEN) and dissolved in water.
Based upon our findings regarding the location of the
transcriptional start site, hapoM-luc constructed with
the human apoM promoter sequences (−3060/0 (P1),
−2207/0 (P2), −1740/0 (P3) and −1189/0 (P4)) were gen-
erated by PCR amplification of corresponding fragments,
and subsequent cloning into Bgl II-Hind III sites of the
pMD-18 T Vetor (TaKaRa Corp). The mutation of
hapoM-luc which bears mutations in the ER-α binding
element was generated by site-directed mutagenesis
using the QiuckChange Site-Directed mutagenesis Kit
(Stratagene) according to the manufacturer’s instruc-
tions. A 2880-bp fragment from 2828 to +52 in the 5'-
flanking region of the USP22 gene was generated by
PCR. The amplified DNA was cloned into pMD 18 T
simple vector and verified by direct sequencing. Other
deletion fragments were generated by PCR using this
plasmid DNA as a template (see Table 1 for PCR primer
sequences). The PCR products were gel-purified,
digested with KpnI and BglII, and subcloned into the
pGL3-basic firefly luciferase vector (Promega). All the
sequences of the cloned promoter region were con-
firmed by DNA sequencing. These sequences of the
USP22 promoter were analyzed for the presence of con-
sensus transcription factor binding sites using the Mat
Inspector program (Genomatix Software GmbH). Site-
directed mutagenesis to inactivate the ER-α binding sites
at positions −1580 to −1575 of the promoter were car-
ried out within the p-210/+52 construct according to
the MutanBEST Kit methodology (TaKaRa Bio) with the
following primers: mutant forward primer, 5′-TTA ATA
AAC TCT AAT ATA CTC ACT GCC CAA ATT TTG
TTT GTT TTT-3′;mutant reverse primer, 5′-AAA AAC
AAA CAA AAT TTG GGC AGT GAG TAT ATT AGA
GTT TAT TAA-3′. All mutations were confirmed by
DNA sequencing.
Cloning of ER-α expression plasmid
Primers were designed with incorporation of Xho I and
EcoRI restriction site. These primers used in the subse-
quence PCR amplification of ER-α were: forward primer,
5′- tac gtc CTC GAG ATG ACC ATG ACC CTC CAC
ACC A-3′, and reverse primer, 5′-ccg GAA TTC TCA
GAC CGT GGC AGG GAA AC-3′. The PCR products
were confirmed by DNA sequencing and digested with
Xho I and EcoRI and inserted into pCDNA3.1.
Transfections and dual luciferase reporter assay
MCF-7 cells were plated in 24-well plates for 24 h before
transfection with 0.5 mg of various apoM promoter con-
structs and 0.1 mg of pRL-TK (Promega) using Lipofec-
tamine 2000 (Invitrogen) in each well. All transfection
experiments were repeated five times. Twenty-four
hours after transfection, cells were washed in phosphate-
buffered saline and lysed for 30 min at room temperature
using passive lysis buffer (Promega). Luciferase activity
was determined using the dual activity was expressed as
the ratio of firefly luciferase activity to Renilla luciferase
for each sample.
Electrophoretic mobility shift assay (EMSA)
Nuclear protein extract was isolated with Nucleoprotein
Extraction Kit (Beyotime). Double-stranded oligonucleo-
tides (Sangon) corresponding to the ER-α binding sites
of the apoM promoter were synthesized and annealed
into double strands. The DNA binding activity of ER-α
protein was detected by LightShift® Chemiluminescent
EMSA Kit (Pierce). 5 μg nuclear protein extract was
added to 1 nmol Biotin-labeled double stranded oligonu-
cleotides, 1 × Binding Buffer, 2.5% Glycerol, 5 mM
MgCl2, 50 ng Poly (dI·dC), 0.1 mM EDTA and 0.05%
NP-40. In addition, control group was added 2 pmol un-
labeled competitor oligonucleotides, while the super-
shift group was added 10 μg ER-α antibody (Santa Cruz).
The mixtures were then incubated at 4 °Cfor 20 min.
The reactions were analyzed by electrophoresis in 6.5%
polyacrylamide gels at 100 V for 1 h, and then trans-
ferred to a nylon membrane. The dried nylon was
scanned with GE ImageQuant LAS4000 mini (GE-
Healthcare).
Chromatin Immunoprecipitation (ChIP) assay
ChIP assays were performed according to the Piece
Agarose Chip Kit (piercenet) manufacturer instructions.
Briefly, MCF-7 cells were fixed by adding formaldehyde
to a final concentration of 1% and incubated by modest
shaking for 10 min at room temperature. Thereafter,
cells were washed twice with cold phosphate-buffered
Table 1 Primers
Name Sequence 5′- 3′ Enzyme site
apoM P1 F ggaAGATCTTCTTGGCAGGCTGATAATTTCAGG BglII
apoM P2 F ggaAGATCTTCACAACTCACTGTAGCCTCTGC BglII
apoM P3 F ggaAGATCTCAGCTTGGGCAACAGAACG BglII
apoM P4 F ggaAGATCTTACCCACCAGAAACTAAGTG BglII
apoM P R ttacccAAGCTTGGAGCTGGTGCTCTGTGTGCC Hind III
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saline. The pellet was resuspended and lysed, and nuclei
were isolated and sonicated until the chromatin had an
average length of 500–1500 bp. After centrifugation, the
supernatant was incubated with 3 mg of antibody against
ER-α overnight at 4 °C for immunoprecipitation. The
following day, Agrose resin was added and the mix was
further incubated at 4 °C for 1 h. After appropriate
washing, the antibody-transcription factor-DNA complex
was eluted, formaldehyde cross-links were reversed, and
proteins were digested with proteinase K at 65 °C 1.5 h.
DNA was purified and used for PCR with primers 5’TTG
GGC AAC AGA ACG AGA CT 3′ and 5’TAT CCC ATG
GAC TGC CAC AA3’. The product sequence is between
−1676 and −1519 bp of apoM promoter.
Statistical analysis
A Prism 6.0 software package (GraphPad Software, Inc.,
CA, USA) was utilized for statistical analysis. The data
were compared by ANOVA and followed by Bonferroni’s
method for multiple comparisons. Significance level was
set at P<0.05.
Results
Estrogen induced up-regulation of apoM expression is via
the ER-α
As shown in Fig. 1a and Fig. 1b, 100 nM BSA-E2 signifi-
cantly upregulated mRNA and protein levels of apoM
(p < 0.05). The stimulatory effects of BSA-E2 on mRNA
and protein levels of apoM in the HepG2 cells were
dose-dependent manner. The ER-α antagonist, MPP,
could abolish the estrogens-induced up-regulation of
apoM (P < 0.05), whereas MPP itself did not significantly
influence mRNA levels of apoM in HepG2 cell cultures
(P > 0.05) (Fig. 1c and Fig. 1d).
Identification of ER-α binding site of the human apoM
promoter
As described in the materials and methods, various trun-
cated apoM promoter were amplified and cloned into
the luciferase reporter vector pMD-18 T Basic and then
were transfected MCF-7 cells. As shown in Fig. 2a, the
P3 (−1740/0 bp), was able to drive expression of the
luciferase reporter gene in MCF-7 13 times higher than
the pGL3-Basic construct, which indicates the 1740
Fig. 1 Effects of estrogens and MPP on the apoM levels of in HepG2 cells. HepG2 cells were cultured with E2-BSA (1 ~ 100 nM) for 24 h
(a and b). HepG2 cells were cultured with E2 (10 μM) or E2-BSA (100 nM) together MPP (1 μM) for 24 h (c and d). The mRNA and pro-
tein levels of apoM were determined as described in the materials and methods. Data are means ± SE. The control groups are represented as 100%.
# P < 0.05 vs control; * P < 0.05 vs E2;**P < 0.01 vs. E2 + BSA
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nucleotides immediately 5' to the transcriptions start site
contain the regulatory elements.
Since the region is required for basal transcriptional
activity of the apoM gene, we substituted CACTG for
the consensus sequence GGTCA (−1580 to −1575 bp)
into the parental vector to generate P3 mutant. After the
transient transfection, P3 mutant construct showed an
approximately 1300% lower luciferase activity in MCF-7
compared with the P3 WT construct, which suggest that
this DNA motif plays a positive role toward apoM pro-
moter activity (Fig. 2b).
Compared with the existing information in the human
genome database, the DNA sequence of the mutation
contains one mutation, GGTCA → CACTG, at position
−1580 and −1575 upstream from the transcriptional
start site (Fig. 2c).
Analysis of the binding of the ER to apoM by EMSA
We next demonstrated the binding of the ER-α to the
apoM promoterusing EMSA. In this assay, we used nu-
clear protein extracts of MCF-7 cells which contained
endogenous ER-α. As shown in Fig.3, lane 1 represents
the free probe. When incubated with biotin-labeled
apoM probe with an MC-7 cell nuclear extract, t a spe-
cific protein-DNA complex was formed (Fig.3 lane 2),
which was supershifted by anti- ER-α antibody (Fig.3
lane 5). The addition of competitor (an unlabeled apoM
probe oligonucleotides) could abrogate the complex
Fig. 2 Characterization of the ER-α response sequence in the apoM gene promoter. a Luciferase reporter assay for the apoM promoter. A series
of truncated apoM promoter-reporter constructs were schematized. Each promoter-reporter construct or the promoter-less plasmid pGL3-basic
was co-transfected with ER-α expression plasmid into MCF-7 cells. After 24 h of transfection, the cells were lysed and measured for firefly and
renilla luciferase activities. The luciferase activity of each construct was presented relative to the pGL3-basic activity. b Mutation analysis of the
ER-α binding site. Luciferase activity expressed by the ER-α site-directed mutant relative to pGL3-basic activity. c Compared with the existing
information in human genome database, the DNA sequence of the mutation contains a mutation region, from −1580 to −1575 upstream from
the transcriptional start site
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formation between the bio-labeled probe and the nuclear
extract (Fig.3 lane 3), but the addition of biotin-labeled
mutant probe cannot inhibit formation of the specific
complexes (Fig.3 lane 4).
Chip analysis of the binding of the ER-α to apoM
To demonstrate that some ER-α binding regions located
in the apoM promoter in intact cells under in vivo con-
ditions, we carried out a ChIP analysis with anti- ER-α
antibody in MCF-7 cells. After chromatin form MCF-7
cells immunoprecipitated with ER-α antibody, we ana-
lyzed the recovered chromatin sampled by RT-PCR.
Data showed that the apoM expression level of anti-ER-
α group was about 12 times that of IgG group (Fig. 4),
which implicated the endogenous ER-α directly bind to
the apoM promoter (sequence between −1676 and
−1519) in MCF-7.
Discussion
apoM is a human apolipoprotein predominantly located
in HDL [1]. Several previous studies showed that some
cytokines and nuclear factors regulate apoM expression,
including platelet activating factor (PAF), leptin, trans-
forming growth factor (TGF), liver x receptor (LXR) and
hepatocyte nuclear factor-1α (HNF-1α) [14–19]. Our
previous study found that estrogen increases apoM
expression. Thus, it is interesting to determine the regu-
latory mechanisms that estrogen controls apoM expres-
sion. We know that estrogen is a physiologic regulator
of blood lipid. However, to date there have been no data
regarding the modulation of apoM expression by estro-
gen. In this study, we used E2 and ER-α antagonist to
treat HepG2 cells to determine the effect of estrogen on
the expression of apoM and its relative signal pathway.
Our results showed that E2 upregulated apoM expres-
sion depending on ER-α which belongs to the nuclear
receptor family of ligand activated transcription factors.
In this study, E2-BSA also induced the transcription of
apoM via membrane ER-α, which is likely contrary to
this opinion that membrane ER-α mediates rapid non-
genomic effects of E2 [20]. But some authors thought
membrane ER-α is also involved genes transcription.
They developed a point mutant ER-α knockin mouse
that precludes palmitoylation and membrane trafficking
of the steroid receptor in all organs. mRNAs implicated
in organ development were often poorly stimulated by
estrogen only in homozygous nuclear-only ER-α mice
[21]. To address the molecular mechanisms underlying
ER-α increased apoM transcription, we performed pro-
moter truncation together with a luciferase activity assay
and site mutation. Results showed that a regulatory re-
gion (−GGTCA-,-1580 to −1575 bp) of the apoM pro-
moter was required for apoM basal transcriptional
activity, and site mutation abolished the transcriptional
activity. The regulatory region (GGTCA) is a half of the
consensus estrogen receptor element (ERE) motifs, ERE
(GGTCA nnn TGACC) is a 13 bp palindromic inverted
repeat with a three nucleotide spacer. Several reports
suggest that many estrogen target genes are regulated by
diverse elements, such as imperfect EREs and ERE half
sites (ERE 1/2), which are either the proximal or the dis-
tal half of palindrome [22–24]. Moreover, we further
confirmed the formation of apoM-ER-α complex in a
protein-DNA style. Some studies have found that there
were some nuclear receptors binding regions in apoM
promoter [19, 25]. Using base deletion analysis combined
Fig. 3 Identification of ER-α responsive element within apoM
promoter by EMSA. nuclear extract isolated from MCF-7 cells
were incubated overnight with different probes with or without
antibody against human ER-α at 4 °C
Fig. 4 Ch IP-PCR assays with ER-α antibody. Chromatin from MCF-7
cells was immunoprecipitated with anti-ER-α or non-immune IgG
(negative control). Input was total chromatin DNA as a positive control,
which was analyzed by RT-PCR. The RT-PCR data are normalized to the
amount of chromatin in the immunoprecipitated reaction. Data are
represented as a ratio of the immunoprecipitated to input DNA
Wei et al. Lipids in Health and Disease  (2017) 16:66 Page 6 of 8
with DNA affinity precipitation and chromatin immuno-
precipitation assays, venteclef and his colleagues revealed
that HNF-4binds to a hormone response element (HRE)
in the proximal apoM promoter (nucleotides −33 to −21).
The importance of ER-αin lipid metabolism is also sup-
ported by some studies which showed a statistical signifi-
cant association between ER-α and abnormalities in LDL
and HDL [26–28]. Figtree and his colleagues found a
novel polymorphism (C > T,ERNE-45) upstream of ER-α
abolished negative transcriptional regulation by an adja-
cent glucocorticoid receptor binding sequence, and was
strongly associated with HDL levels in a large cohort of
post-menopausal woman [28].
In this study, we showed apoM as a novel target gene
of hormone nuclear receptor ER-α. Some previous stud-
ies found some nuclear receptors regulate apoM expres-
sion, including Liver receptor homologue-1 (LRH-1),
HNF-4 and LXR [18, 19, 25]. In one of our previous
studies, Zhang et al. found that oral administration of
the synthetic LXR agonist T09031317 in mice was asso-
ciated with a down-regulation in basal apoM mRNA
levels in the liver. In another study, it is shown that the
orphan nuclear receptor liver receptor homolog-1, LRH-
1 directly regulates human and mouse apoM transcrip-
tion by binding to an LRH-1 response element located
in the proximal apoM promoter region. In addition, the
authors demonstrated that bile acids suppress apoM
expression in a SHP-dependent mannaer in vitro and in
vivo by inhibiting LRH-1transcriptional activity on the
apoM promoter. ApoA-I is also the main structural
protein in HDL. Therefore, we speculated that activated
of ER-α may contribute to increasing of apoM
transcription.
Conclusions
We have investigated the effects of estrogens on regula-
tion of expression of apoM gene, indicating that
estrogens-induced increasing of apoM transcriptional
activity is mediated through ER-α binding region in the
apoM promoter.
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